This clinical trial is for men and women with locally advanced or metastatic solid tumor malignancies who have progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy.

The purpose of this study is to evaluate the safety and effectiveness of KB707. KB707 is experimental, which means that it is being tested and is not yet approved by the United States Food and Drug Administration (FDA).

This clinical trial is for men and women who have mantle cell lymphoma, a sub-type of B-cell non-Hodgkin lymphoma, who have never received treatment for their disease before.

The purpose of this study is to see if an experimental drug, called milvexian in addition to standard of care, is safe and useful in reducing the risk of future ischemic stroke in subjects after ischemic stroke or transient ischemic attack compared to placebo (tablet with no active drug) in addition to standard of care. This research is important to future patients, as this knowledge may help doctors do a better job of preventing stroke in patients.

Experimental means that milvexian has not yet been approved by the U.S. Food and Drug Administration (FDA). 

The purpose of this research study is to see whether ticagrelor and aspirin or rivaroxaban and aspirin compared to clopidogrel and aspirin may have the most success in preventing another stroke, bleed in the brain, or death in participants who have already had a stroke from a narrowed brain artery. This research is important to future patients, as this knowledge may help doctors do a better job of preventing stroke in patients with major narrowing of brain arteries.

The purpose of this study is to evaluate the safety and efficacy of OBP-301 with pembrolizumab in advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma (gastroesophageal adenocarcinoma).
   
OBP-301 is experimental, which means that it in combination with pembrolizumab is being tested and they are not yet approved by the United States Food and Drug Administration (FDA). 

This clinical trial is for adult participants who have primary antiphospholipid syndrome (APS). APS is a rare and chronic autoimmune disorder, meaning that it occurs when the body's immune system mistakenly attacks healthy tissues and organs. APS is common in patients with other autoimmune or rheumatic diseases, particularly systemic lupus erythematosus (SLE). APS is referred to as "primary" when it occurs alone. Participants in this study have been diagnosed with primary APS.
   

This clinical trial is for men and women who have high-risk large B-cell lymphoma (LBCL) and standard therapies available to treat their disease have limited effectiveness.
   

This clinical trial is for adult men who have metastatic prostate cancer. This trial has multiple arms, or portions. Participants will only take part in one portion of the study.
   
The purpose of the first portion of this study is to assess the safety and tolerability (good and bad effects) and how prostate cancer responds to two different doses of the investigational study drug ARV-766 in men with metastatic prostate cancer who have progressed on prior approved systemic therapies for disease like theirs.
   

This study is evaluating an alternative treatment for glucose control. The treatment is with a device called the EndoBarrier® System. It is an experimental device that may help to treat diabetes where medications, diet, and exercise alone have not achieved enough improvement.

The EndoBarrier® System is considered investigational which means it is not currently approved by the U.S. Food and Drug Administration (FDA).

This study is investigating Blinatumomab in combination with chemotherapy in patients with newly diagnosed standard risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the treatment of patients with localized B-Lymphoblastic Lymphoma (B-LLy).

Blinatumomab is an investigational drug which means it has not yet been approved by the U.S. Food and Drug Administration (FDA).